{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:12:22Z","timestamp":1790874742340,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fundaci\u00f3 Instituci\u00f3 dels Centres de Recerca de Catalunya"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Line blot assays (LBA) have several limitations regarding diagnostic validity, as sensitivity and specificity vary considerably among antigens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to assess whether the adjustment of each specific band intensity (BI) relative to the positive control band (PCB), combined with increasing the cut-off value from 15 to 20, improves the diagnostic performance of the LBA for detecting autoantibodies related to idiopathic inflammatory myopathies in our patient cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included all serum samples tested for myositis\u2011specific antibodies (MSA) and myositis\u2011associated antibodies (MAA) between January 2022 and April 2023 at the Immunology Department of Hospital Cl\u00ednic of Barcelona. Two analyses were performed: Analysis A, using the manufacturer\u2019s recommended cut-off (BI\u2009\u2265\u200915), and Analysis B, applying the proposed BI adjustment relative to the PCB and raising the cut-off to 20 in samples that were positive in Analysis A.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 939 patients were included. Using Analysis A, 280\/939 (29.8%) patients had at least one positive result, whereas 659\/939 (70.2%) were negative for all MSA and MAA. After applying Analysis B, 151\/280 (53.9%) remained positive, while 129\/280 (46.1%) became negative. With Analysis A, sensitivity was 76%, specificity 75%, positive predictive value (PPV) 24%, and negative predictive value (NPV) 96%. Under Analysis B, sensitivity was 70%, specificity 89%, PPV 41%, and NPV 96%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Applying the proposed BI adjustment effectively removes weakly positive results with low specificity in an objective and reproducible manner, thereby increasing the overall specificity of the LBA.<\/jats:p>\n                    <jats:p>\n                      <jats:table-wrap>\n                        <jats:table>\n                          <jats:tbody>\n                            <jats:tr>\n                              <jats:td align=\"left\" colspan=\"2\">\n                                <jats:bold>Key Points<\/jats:bold>\n                                \u2022\n                                <jats:italic>Applying the proposed band intensity removes weakly positive results<\/jats:italic>\n                                .\u2022\n                                <jats:italic>This approach enhances the specificity, and positive predictive value of a commercial line blot assay<\/jats:italic>\n                                .\n                              <\/jats:td>\n                            <\/jats:tr>\n                          <\/jats:tbody>\n                        <\/jats:table>\n                      <\/jats:table-wrap>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-026-08153-4","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:14:48Z","timestamp":1779855288000},"page":"4391-4397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing line blot assays: impact of band intensity adjustment on diagnostic performance in myositis autoantibodies testing"],"prefix":"10.1007","volume":"45","author":[{"given":"Francisco Javier","family":"H\u00fcttmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"P\u00e9rez-Isidro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Ortiz-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Torradeflot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"de Moner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Hern\u00e1ndez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2628-5932","authenticated-orcid":false,"given":"Est\u00edbaliz","family":"Ruiz-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Prieto-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"8153_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40257-020-00502-6","volume":"21","author":"GA Cobos","year":"2020","unstructured":"Cobos GA, Femia A, Vleugels RA (2020) Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol 21:339\u2013353. https:\/\/doi.org\/10.1007\/s40257-020-00502-6","journal-title":"Am J Clin Dermatol"},{"key":"8153_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11926-024-01164-7","volume":"26","author":"J Musai","year":"2024","unstructured":"Musai J, Mammen AL, Pinal-Fernandez I (2024) Recent updates on the pathogenesis of inflammatory myopathies. Curr Rheumatol Rep 26:421\u2013430. https:\/\/doi.org\/10.1007\/s11926-024-01164-7","journal-title":"Curr Rheumatol Rep"},{"key":"8153_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41572-021-00325-7","volume":"7","author":"Idiopathic inflammatory myopathies","year":"2021","unstructured":"Idiopathic inflammatory myopathies (2021) Nat Rev Dis Primer 7:87. https:\/\/doi.org\/10.1038\/s41572-021-00325-7","journal-title":"Nat Rev Dis Primer"},{"key":"8153_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41584-024-01188-4","volume":"21","author":"NA Allameen","year":"2025","unstructured":"Allameen NA, Ramos-Lisbona AI, Wedderburn LR, Lundberg IE, Isenberg DA (2025) An update on autoantibodies in the idiopathic inflammatory myopathies. Nat Rev Rheumatol 21:46\u201362. https:\/\/doi.org\/10.1038\/s41584-024-01188-4","journal-title":"Nat Rev Rheumatol"},{"key":"8153_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","volume":"14","author":"NJ McHugh","year":"2018","unstructured":"McHugh NJ, Tansley SL (2018) Autoantibodies in myositis. Nat Rev Rheumatol 14:290\u2013302. https:\/\/doi.org\/10.1038\/nrrheum.2018.56","journal-title":"Nat Rev Rheumatol"},{"key":"8153_CR6","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1093\/rheumatology\/keq281","volume":"49","author":"A Ghirardello","year":"2010","unstructured":"Ghirardello A, Rampudda M, Ekholm L, Bassi N, Tarricone E, Zampieri S et al (2010) Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology 49:2370\u20132374. https:\/\/doi.org\/10.1093\/rheumatology\/keq281","journal-title":"Rheumatology"},{"key":"8153_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","volume":"52","author":"M Satoh","year":"2017","unstructured":"Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EKL (2017) A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 52:1\u201319. https:\/\/doi.org\/10.1007\/s12016-015-8510-y","journal-title":"Clin Rev Allergy Immunol"},{"key":"8153_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.autrev.2009.03.005","volume":"9","author":"J R\u00f6nnelid","year":"2009","unstructured":"R\u00f6nnelid J, Barbasso Helmers S, Storfors H, Grip K, R\u00f6nnblom L, Franck-Larsson K et al (2009) Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev 9:58\u201361. https:\/\/doi.org\/10.1016\/j.autrev.2009.03.005","journal-title":"Autoimmun Rev"},{"key":"8153_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2016.02.017","volume":"433","author":"I Cavazzana","year":"2016","unstructured":"Cavazzana I, Fredi M, Ceribelli A, Mordenti C, Ferrari F, Carabellese N et al (2016) Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera. J Immunol Methods 433:1\u20135. https:\/\/doi.org\/10.1016\/j.jim.2016.02.017","journal-title":"J Immunol Methods"},{"key":"8153_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151998","volume":"55","author":"E Bories","year":"2022","unstructured":"Bories E, Fortenfant F, Pugnet G, Renaudineau Y, Bost C (2022) Myositis-specific autoantibodies in clinical practice: improving the performance of the immunodot. Semin Arthritis Rheum 55:151998. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151998","journal-title":"Semin Arthritis Rheum"},{"key":"8153_CR11","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","volume":"59","author":"SL Tansley","year":"2020","unstructured":"Tansley SL, Li D, Betteridge ZE, McHugh NJ (2020) The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. Rheumatology 59:2109\u20132114. https:\/\/doi.org\/10.1093\/rheumatology\/keaa021","journal-title":"Rheumatology"},{"key":"8153_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.pathol.2016.03.012","volume":"48","author":"C Bundell","year":"2016","unstructured":"Bundell C, Rojana-udomsart A, Mastaglia F, Hollingsworth P, McLean-Tooke A (2016) Diagnostic performance of a commercial immunoblot assay for myositis antibody testing. Pathology (Phila) 48:363\u2013366. https:\/\/doi.org\/10.1016\/j.pathol.2016.03.012","journal-title":"Pathology (Phila)"},{"key":"8153_CR13","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00296-023-05287-5","volume":"43","author":"SH Chang","year":"2023","unstructured":"Chang SH, Choi SR, Choi YS, Go DJ, Park JW, Ha Y-J et al (2023) Performance of cut-offs adjusted with positive control band intensity in line-blot assays for myositis-specific antibodies. Rheumatol Int 43:1507\u20131513. https:\/\/doi.org\/10.1007\/s00296-023-05287-5","journal-title":"Rheumatol Int"},{"key":"8153_CR14","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, Werth VP, Pilkington C, Visser MD et al (2017) 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955\u20131964. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468","journal-title":"Ann Rheum Dis"},{"key":"8153_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/art.43038","volume":"77","author":"S Faghihi-Kashani","year":"2025","unstructured":"Faghihi-Kashani S, Yoshida A, Bozan F, Zanframundo G, Rozza D, Loganathan A et al (2025) Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project. Arthritis Rheumatol 77:477\u2013489. https:\/\/doi.org\/10.1002\/art.43038","journal-title":"Arthritis Rheumatol"},{"key":"8153_CR16","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","volume":"78","author":"J Damoiseaux","year":"2019","unstructured":"Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ et al (2019) Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis 78:879\u2013889. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214436","journal-title":"Ann Rheum Dis"},{"key":"8153_CR17","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/1756-185X.14174","volume":"24","author":"TJ Beaton","year":"2021","unstructured":"Beaton TJ, Gillis D, Prain K, Morwood K, Anderson J, Goddard J et al (2021) Performance of myositis\u2010specific antibodies detected on myositis line immunoassay to diagnose and sub\u2010classify patients with suspected idiopathic inflammatory myopathy, a retrospective records\u2010based review. Int J Rheum Dis 24:1167\u20131175. https:\/\/doi.org\/10.1111\/1756-185X.14174","journal-title":"Int J Rheum Dis"},{"key":"8153_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/art.41088","volume":"72","author":"CA Mecoli","year":"2020","unstructured":"Mecoli CA, Albayda J, Tiniakou E, Paik JJ, Zahid U, Danoff SK et al (2020) Myositis autoantibodies: a comparison of results from the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun Research Line Blot. Arthritis Rheumatol 72:192\u2013194. https:\/\/doi.org\/10.1002\/art.41088","journal-title":"Arthritis Rheumatol"},{"key":"8153_CR19","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1136\/annrheumdis-2017-212915","volume":"78","author":"J-B Vulsteke","year":"2019","unstructured":"Vulsteke J-B, De Langhe E, Claeys KG, Dillaerts D, Poesen K, Lenaerts J et al (2019) Detection of myositis-specific antibodies. Ann Rheum Dis 78:e7-10. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212915","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08153-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08153-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08153-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:27:49Z","timestamp":1783398469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08153-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8153"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08153-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was reviewed and approved by the Clinical Research Ethics Committee (CEIm) of Hospital Cl\u00ednic de Barcelona (reference: HCB\/2022\/0923 \u2013 Study of the humoral immune response in patients with autoimmune disease).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}